The global non-insulin therapies for diabetes market is slated
to grow on an exponential note with a sizable increase in incidence
of type 2 diabetes followed by governments and non-government
agencies collaborating to devise better measures to cure it, with
non-insulin therapies being the epicentre.
WILMINGTON, Del., Aug. 1, 2024 /PRNewswire/ -- The global
non-insulin therapies for diabetes market is forecast to advance at
a CAGR of 5.8% from 2024 to 2034. As per TMR's estimates,
the market is slated to attain a US$ 58.6
billion valuations by the end of the aforementioned
forecast period. As of 2023, the landscape was valued at
US$ 31.8 billion.
Non-insulin therapies are generally preferred by healthcare
personnel in patients suffering from type 2 diabetes, in which body
either fails to produce enough insulin or is incapable of using the
insulin that it produces. Certain non-insulin agents facilitate
increase of insulin release from the pancreatic cells
(sulfonylureas), whereas some of them increase glucose uptake
peripherally and reduce hepatic glucose output (Biguanides).
There are agents slowing down digestion of starch in the small
intestine (alpha glucosidase inhibitors). Certain medications
facilitate reduction of post-meal sugar by blocking some enzymes
(Incretin mimetics). The last decade has seen a drastic rise in
launching and approvals of non-insulin therapies for diabetes.
Various drugs under the category of SGL2 inhibitors such as
Empagliflozin, Canagliflozin, and Dapagliflozin were launched after
2013.
Request for sample PDF copy of report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328
Type 2 diabetes occurs in adults when body turns out to be
resistant to insulin or does not produce insulin sufficient for the
body. In other words, type 2 diabetes happens due to improper
regulation of body sugar as fuel. As per the World Health
Organization, 422 million people worldwide are living with
diabetes, with 1.5 million succumbing to it. Need to combat type 2
diabetes through non-insulin therapies is thus driving the
non-insulin therapies for diabetes market.
Key Takeaways from the Market Study
- A valuation of US$ 33.6 billion
is anticipated for the non-insulin therapies for diabetes market in
2024.
- From 2024 to 2034, the market for non-insulin therapies for
diabetes is slated to expand 1.7x.
- By drug class, demand for SGLT2 inhibitors is anticipated to
flourish throughout the forecast period, attributed to their
minimal side effects.
- Intramuscular administration of non-insulin therapies for
diabetes to acquire greater popularity, amid the need for enhanced
effectiveness.
Key Drivers and Trends
- Non-insulin-based drugs for diabetes work toward the direction
of lessening blood glucose level and keeping up for ideal glycemic
control. For instance, certain operators increment insulin
discharge from the pancreatic cells (Sulfonylureas), certain
specialists increment the glucose take-up and decrease yield of
hepatic glucose (Biguanides).
- Some operators curtail assimilation of starch in the small
digestive tract (alpha glucosidase inhibitors), and some
prescriptions diminish post-supper sugar by obstruction of some
chemicals.
- The World Health Organization states that diabetes is amongst
the top 3 causes of fatalities amongst the non-communicable
diseases across the globe. Governments are collaborating with
various research institutes, hospitals, and non-government agencies
to create awareness regarding type 2 diabetes and curative measures
regarding the same.
Non-Insulin Therapies for Diabetes Market Report
Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 31.8 Bn
|
Forecast (Value) in
2034
|
US$ 58.6 Bn
|
Growth Rate
(CAGR)
|
5.8 %
|
No. of
Pages
|
142
Pages
|
Segments
covered
|
By Drug Class, By Route
of Administration, By Distribution Channel, By Region
|
Unlock Growth Potential in Your Industry! Download PDF
Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328
Regional Profile
- North America dominated the
non-insulin injection landscape in 2023 and the scenario is
expected to persist during the forecast period. This is attributed
to rise in incidence of type 2 diabetes in the U.S. followed by
sizable spending on healthcare.
- As per the Centers for Disease Control and Prevention, over 38
million Americans suffer from diabetes, with around 90-95%
contracting type 2 diabetes.
- Asia Pacific is another
promising investment hub for non-insulin therapy providers.
Asia Pacific's non-insulin
therapies for diabetes market growth is ascribed to growing
awareness about the importance of non-insulin treatments for type 2
diabetes.
- As per the National Institutes of Health, 23-30% of the youth
over here suffers from type 2 diabetes and the percentage is
expected to rise during the forecast period.
Competitive Landscape
From organizing clinical trials to seeking regulatory approval,
the non-insulin therapies for diabetes landscape is experiencing
noteworthy developments. Companies are pooling in a substantial
amount of resources to fund trials and research and development
projects. Some key providers of non-insulin therapies for diabetes
include:
- GSK plc
- Eli Lilly and Company
- Sumitomo Pharma
- Intarcia Therapeutics
- Servier Laboratories
- Pfizer Inc.
- Merck & Co. Inc.
- Dong-A Pharmaceutical Co. Ltd.
- Luye Pharma Group
- Eurofarma Laboratories SA
Key Market Developments
- In April 2024, GSK Plc announced that the U.S.
Food and Drug Administration has approved its
TazneumTM (albiglutide) product for injection and
subcutaneous use for a once-a-week treatment for type 2 diabetes.
Albigludite is a glucagon-like peptide-1 receptor agonist (GLP-1)
for treating the condition.
- In June 2023, Pfizer
Inc. provided update on GLP-1-RA clinical development program
for the adults suffering from obesity and type 2 diabetes mellitus,
stating that it is continuing with advancement of the first full
agonist oral candidate danudlipron toward late-state
development.
Key Segments Covered
Drug Class
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- DPP-4 Inhibitors
- GLP-1 Analogs
- Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
Route of Administration
End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86328<ype=S
More Trending Reports by Transparency Market Research
–
- Consumer Genomics Market - The global consumer
genomics market was estimated to have acquired US$ 2.4 billion in 2021. It is anticipated to
register a 22.3% CAGR from 2022 to 2032 and by 2032, the market
is likely to gain US$ 21.2
billion.
- Acute Migraine Treatment Market - The global
market for acute migraine treatment was estimated to be worth a
market valuation of around US$ 2.1
billion in 2021. The market is anticipated to advance with a
booming 15.1% CAGR from 2023 to 2031 and by 2031, the market
is likely to gain US$ 7.9
billion.
- Ceftriaxone Market - The global ceftriaxone
market is projected to flourish at a CAGR of 2.9% from 2022
to 2031. A valuation of US$ 2.2
billion is anticipated for the market in 2031. As of 2023,
the market for ceftriaxone is expected to close at US$ 1.79 billion.
- Fusion Inhibitors Market - The fusion inhibitors
market attained US$ 295.3 million in
2021. The market is likely to gain US$ 7.2
billion by 2031 securing a CAGR of 14.2% between 2022
and 2031.
About Transparency Market Research
Transparency Market Research, a global market research
company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter|
Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/non-insulin-therapies-for-diabetes-market-to-reach-usd-58-6-billion-by-2034--driven-by-innovative-drug-mechanisms-and-rising-global-awareness--states-tmr-302212359.html